-

Croma-Pharma GmbH expands its portfolio introducing pure HA

Hyaluronic acid without distraction

LEOBENDORF, Austria--(BUSINESS WIRE)--Croma is always committed to deepening its product portfolio to support customers in their daily work. With pure HA, Croma has developed a highly concentrated liquid skin mask in a minimalistic formula containing 1.8% of hyaluronic acid to smooth, moisturize and revitalize the skin while boosting its natural hydration.

Containing ingredients normally used in medical and aesthetic practices, Croma wants to bring the usual high quality of pharma grade hyaluronic acid to skincare used at home. Pure and without distraction.

"With pure HA, we have developed a skincare product based on hyaluronic acid that complies with the high standards of our medical devices, complements our existing portfolio perfectly and underlines Croma's claim as an expert in hyaluronic acid", remarked Andreas Prinz, Managing Director of Croma.

With a silky, lightweight texture suitable for all skin types, pure HA aims to make the skin feel nourished and radiant. Produced in a sterile and high professional glass container, pure HA brings a pharmaceutical approach to skincare at home – from the experts of hyaluronic acid.

About Hyaluronic Acid

Hyaluronic acid is one of the most essential ingredients in skincare today. Hyaluronic acid revitalizes the skin and at the same time strengthens its natural moisture content. It optimizes the skin's elasticity, plumps the skin and improves the appearance of fine lines and wrinkles.

About Croma-Pharma GmbH

Founded in 1976, Croma-Pharma GmbH (Croma) is an Austrian family-owned company that specializes in the industrial production of hyaluronic acid syringes for the fields of medical aesthetics, ophthalmology and orthopaedics. Croma currently runs 12 international sales companies and distributes its products in more than 70 countries. Within its global sales network, Croma focuses with own branded products on minimally invasive aesthetic medicine. Besides a broad range of HA fillers from the own production site, Croma markets PDO lifting threads, a Platelet Rich Plasma (PRP) system and innovative skincare technologies in its core strategic markets.

Contacts

CROMA-PHARMA GmbH
Stefanie Höhn
Global Director Communications
Cromazeile 2
A-2100 Leobendorf
Phone: +43 676 846868 190
Mail: stefanie.hoehn@croma.at
Web: www.croma.at

Croma-Pharma GmbH


Release Summary
With pure HA, Croma has developed a highly concentrated liquid skin mask in a minimalistic formula containing 1.8% of hyaluronic acid.

Contacts

CROMA-PHARMA GmbH
Stefanie Höhn
Global Director Communications
Cromazeile 2
A-2100 Leobendorf
Phone: +43 676 846868 190
Mail: stefanie.hoehn@croma.at
Web: www.croma.at

Social Media Profiles
More News From Croma-Pharma GmbH

Croma Skincare – Where Science Meets Skin

LEOBENDORF, Austria--(BUSINESS WIRE)--With Croma Skincare, Austrian family-owned company Croma Pharma translates decades of expertise in aesthetic medicine into a modern skincare line designed for everyday results. Rather than following short-lived trends, Croma focuses on scientifically proven ingredients and pharmaceutical-grade formulations that deliver visible performance while fitting seamlessly into daily routines. Building on 50 years of experience in hyaluronic acid, Croma Pharma develo...

Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform

LEOBENDORF, Austria--(BUSINESS WIRE)--Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics....

Croma-Pharma Acquires Synocrom™ and Returns to Orthopaedics

LEOBENDORF, Austria--(BUSINESS WIRE)--Croma-Pharma is returning to the orthopaedics market with the reacquisition of Synocrom™, a hyaluronic acid product for the treatment of knee osteoarthritis. A strategic return built on proven heritage With the reacquisition of Synocrom™, Croma-Pharma is re-entering orthopaedics and further broadening its portfolio in a field with strong historical roots for the company. Until 2014, Croma was active in orthopaedics, with Synocrom™ serving as a key pillar of...
Back to Newsroom